This database contains 145 studies, archived under the term: "activities of daily living"
Click here to filter this large number of results.
Effect of shunt operation on idiopathic normal pressure hydrocephalus patients in reducing caregiver burden: evidence from SINPHONI
Kazui, Hiroaki,
Mori, Etsuro,
Hashimoto, Masaaki,
Ishikawa, Masatsune,
Hirono, Nobutsugu,
Takeda, Masatoshi
Background/aims: Patients with idiopathic normal pressure hydrocephalus (iNPH) are often given shunt operations to reduce the triad symptoms (cognitive impairment, gait disturbance and urinary disturbance). We examined whether they also reduce caregiver burden.; Methods: The personal strain (PS) and role strain (RS) factors, which are related to the stress and constraints, respectively, on the caregivers […]
Electronic organiser and Alzheimer’s disease: fact or fiction?
Imbeault, Hélène,
Bier, Nathalie,
Pigot, Hélène,
Gagnon, Lise,
Marcotte, Nicolas,
Fulop, Tamas,
Giroux, Sylvain
Alzheimer’s disease is a degenerative disease characterised by a progressive loss of cognitive functions and impairment of activities of daily living severe enough to interfere with normal functioning. To help persons with this disease perform a variety of activities, our research team developed AP@LZ, an electronic organiser specifically designed for them. Two participants with Alzheimer’s […]
Memantine effects measured with the Relevant Outcome Scale for Alzheimer’s disease in an open-label, single-arm, multicenter clinical study
Holthoff, Vjera,
Ferris, Steven,
Gauthier, Serge,
Ihl, Ralf,
Robert, Philippe,
Winblad, Bengt,
Sternberg, Kati,
Tennigkeit, Frank
Objective: The Relevant Outcome Scale for Alzheimer’s disease (ROSA) is a novel, valid, and reliable instrument for multidimensional assessment of Alzheimer’s disease (AD) symptoms across all severity stages. The ROSA and four standard instruments — the Alzheimer’s disease Assessment Scale-cognitive (ADAS-cog), Severe Impairment Battery (SIB), Disability Assessment for Dementia (DAD), and the Neuropsychiatric Inventory (NPI) […]
Efficacy of higher dose 13.3 mg/24 h rivastigmine patch on instrumental activities of daily living in patients with mild-to-moderate Alzheimer’s disease
Grossberg, G.,
Cummings, J.,
Frolich, L.,
Bellelli, G.,
Molinuevo, J. L.,
Krahnke, T.,
Strohmaier, C.
Background: Stabilizing/reducing decline in the ability to perform activities of daily living (ADLs) is important in management of Alzheimer’s disease (AD).; Methods: Post hoc analysis of OPtimizing Transdermal Exelon In Mild-to-moderate Alzheimer’s disease (OPTIMA), a double-blind trial comparing 13.3 and 9.5 mg/24 h rivastigmine patch in patients with AD demonstrating functional and cognitive decline with […]
Helping carers to care–the 10/66 dementia research group’s randomized control trial of a caregiver intervention in Russia
Gavrilova, Svetlana I.,
Ferri, Cleusa P.,
Mikhaylova, Natalya,
Sokolova, Olga,
Banerjee, Sube,
Prince, Martin
Objectives: Dementia is a rapidly growing public health problem in low and middle income countries. There is an urgent need, in the absence of formal services, to develop interventions designed to improve the lives of people with dementia, and their families. This study tests the effectiveness of the 10/66 caregiver intervention among people with dementia, […]
Retrospective study on the benefits of combined Memantine and cholinEsterase inhibitor treatMent in AGEd Patients affected with Alzheimer’s Disease: the MEMAGE study
Gareri, Pietro,
Putignano, Daria,
Castagna, Alberto,
Cotroneo, Antonino Maria,
De Palo, Grazia,
Fabbo, Andrea,
Forgione, Luigi,
Giacummo, Attilio,
Lacava, Roberto,
Marino, Saverio,
Simone, Maurizio,
Zurlo, Amedeo,
Putignano, Salvatore
Background: Combined therapy of memantine and acetylcholinesterase inhibitors (AChEIs) in patients with Alzheimer’s disease (AD) may be associated with higher benefits than either monotherapy.; Objective: This retrospective multicentric study conducted in seven Italian Ambulatory Centers for Dementia assessed the efficacy and safety of memantine 20 mg/day administered for 6 months in addition to an AChEI […]
Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial
Dysken, Maurice W.,
Sano, Mary,
Asthana, Sanjay,
Vertrees, Julia E.,
Pallaki, Muralidhar,
Llorente, Maria,
Love, Susan,
Schellenberg, Gerard D.,
McCarten, J. Riley,
Malphurs, Julie,
Prieto, Susana,
Chen, Peijun,
Loreck, David J.,
Trapp, George,
Bakshi, Rajbir S.,
Mintzer, Jacobo E.,
Heidebrink, Judith L.,
Vidal-Cardona, Ana,
Arroyo, Lillian M.,
Cruz, Angel R.,
Zachariah, Sally,
Kowall, Neil W.,
Chopra, Mohit P.,
Craft, Suzanne,
Thielke, Stephen,
Turvey, Carolyn L.,
Woodman, Catherine,
Monnell, Kimberly A.,
Gordon, Kimberly,
Tomaska, Julie,
Segal, Yoav,
Peduzzi, Peter N.,
Guarino, Peter D.
Importance: Although vitamin E and memantine have been shown to have beneficial effects in moderately severe Alzheimer disease (AD), evidence is limited in mild to moderate AD.; Objective: To determine if vitamin E (alpha tocopherol), memantine, or both slow progression of mild to moderate AD in patients taking an acetylcholinesterase inhibitor.; Design, Setting, and Participants: […]